The Anti-Dopamine Receptor D1 (DRD1) test measures autoantibodies directed against the D1 dopamine receptor, an important signaling receptor found in regions of the brain responsible for behavior, mood, movement control, executive function, and emotional regulation. The presence of these antibodies may indicate that the immune system is mistakenly targeting neuronal structures—a process known as autoimmune or immune-mediated neuroinflammation.
D1 receptors play a key role in dopamine signaling, affecting reward pathways, memory, decision-making, motor coordination, and impulse control. When antibodies bind to these receptors, they may alter dopamine activity and contribute to sudden or severe neuropsychiatric symptoms. Elevated DRD1 titers have been reported in children and adolescents experiencing symptoms associated with PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome), PANDAS, Sydenham chorea, and other immune-triggered neurological conditions.
This marker is part of the Autoimmune Brain Panel™, which evaluates autoantibodies thought to influence neuronal pathways. While the presence of DRD1 antibodies is not diagnostic on its own, it provides valuable supporting evidence when combined with clinical symptoms and other immune markers such as anti-DNase B, ASO, and other neuronal autoantibodies (DRD2L, anti-tubulin, anti-lysoganglioside GM1).
Results should be interpreted alongside the full panel and a clinician’s assessment, as titers can vary and must be understood in clinical context.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.